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Introduction
It is our privilege and pleasure to present in this Kidney The articles nicely reflect the forum for the invaluable
International supplement the proceedings of the Interna- exchange of recent scientific thoughts and experiences
tional Congress on Uremic Toxicity, held in the stimulat- in the broad spectrum of preclinical and clinical topics
ing historic atmosphere of Wu¨rzburg, Germany, Septem- related to uremia and the cardiovascular system that this
ber 13–16, 2002. congress provided. It, therefore, made a great impact on
More than 250 participants from around the world took those who attended to promote new scientific research
part in this fruitful meeting, focusing on novel aspects of and therapeutic approaches for the understanding and
uremia and the cardiovascular system. The aim of this treatment of uremic conditions.
Congress was to provide up-to-date information about We would like to thank all of the speakers and authors
major advances in the understanding and treatment of for their contributions. We sincerely hope that this Sup-
uremia-associated conditions and their cardiovascular plement allows those who were not able to participate
consequences. This supplement contains articles drawn in the Congress to share the novel and insightful ideas
from the lectures presented and discussed in the produc- that were presented.
tive atmosphere of the congress venue, including the Publication of this Supplement was made possible
following topics: the relevance of uremic toxicity; oxida- by generous grants from Baxter Healthcare Corpora-
tive stress and nitric oxide (NO); endothelial dysfunction; tion, Fresenius Medical Care, Gambro Medizintechnik
the role of inflammation; cytokines and the immune sys- GmbH, OrthoBiotech Division of Janssen Cilag GmbH,
tem; metabolism and inflammation; the impact of dyslipi- and Pfizer GmbH.
demias; the importance of homocysteine; carbonyl stress
and advanced glycation end products (AGEs); uremia, Thomas Quaschning and Christoph Wanner
Guest Editorsgenes, and the heart; and epidemiology and clinical trials.
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